Daily Cosmetic Research Analysis

The assessment of coronal balance is critical for cosmetic appearance and quality of life in patients with adolescent idiopathic scoliosis (AIS), yet its manual quantification remains constrained by substantial workflow demands and inherent subjectivity. While artificial intelligence has shown promise in automated Cobb angle measurement, robust and clinically safety-aware solutions for coronal balance parameters are still lacking. In this study, we developed and validated a robust HRNet-based automated system for quantifying Shoulder Height Difference (SHD), Pelvic Obliquity (PO), and C7 Plumb Line Offset (C7 offset) using a dataset of 847 full-spine radiographs. Beyond anatomically driven topological constraints, we integrated a novel Clinical Safety Gating Mechanism that proactively suppresses unreliable outputs in cases of anatomical ambiguity, functioning as a safety gating by design. The system achieved millimeter-level precision (mean absolute error: 0.86-2.45 mm) and demonstrated strong agreement with manual reference measurements (Pearson r > 0.95), with overall performance approximating the inter-rater variability among senior spinal surgeons. Importantly, the deterministic algorithmic consistency of the system mitigates human fatigue and subjective fluctuation, offering theoretical advantages for future longitudinal assessments. Collectively, this work positions the automated coronal balance system not merely as a measurement tool, but as a safety-aware quality safety gating mechanism. These findings validate the technical feasibility and internal safety of the model, providing a robust foundation for large-scale clinical data auditing and future prospective studies on long-term patient outcomes.

As the cosmetic industry replaces traditional animal safety studies with next generation risk assessment approaches, the approach to safety substantiation for peptides used in cosmetic products must also evolve. While the need to provide assurances of safety for local and systemic toxicity endpoints remains the same, adoption of bioinformatic tools developed in the food, agricultural biotechnology, and drug development industries may add to the weight of evidence for the safety substantiation of peptides in cosmetics. Here we review the historical development and safety evaluation of peptides utilized in the cosmetic industry and provide a new safety evaluation framework that incorporates six bioinformatic tools. To test the framework, a variety of peptides (palmitoyl hexapeptide-12, caffeoyl hexapeptide-9, palmitoyl pentapeptide-4, amanitin alpha, conotoxin ArlB, bradykinin, and enkephaline) are evaluated with NCBI BLASTp, ToxinPred3.0, Peptipedia, BIOPEP-UWM, AllerCatPro 2.0, and IEDB bioinformatic tools. The results correctly identified safety concerns (toxins) for amanitin and conotoxin peptides and the biological actions of bradykinin and enkephaline, while palmitoyl hexapeptide-12, caffeoyl hexapeptide-9, and palmitoyl pentapeptide-4 demonstrated sequence homology with extracellular matrix proteins in the skin (collagen, elastin, fibronectin) without the safety concerns of the other peptides. The incorporation of bioinformatic tools into the safety framework provides an additional means to screen for toxins and allergens as well as insights into potential biological activities when sequence homology with existing proteins and peptides occurs. Further testing of the framework by the cosmetic industry is needed to lend support and reveal opportunities for refinements that advance the safety substantiation of peptides.

BACKGROUND: Moderate hypofractionation is established as the standard of care for adjuvant whole-breast radiotherapy after breast-conserving surgery. Ultra-hypofractionated regimens further shorten treatment but have raised concerns about toxicity and cosmetic outcomes. In younger Asian patients frequently requiring a boost, we evaluated a 10-fraction whole-breast radiotherapy schedule as a practical and tolerable choice. METHODS: This single-arm, prospective phase II trial enrolled 64 patients with early-stage breast cancer at Peking University Cancer Hospital between November 2023 and March 2025. All patients received intensity-modulated radiotherapy (IMRT) with a prescribed dose of 37 Gy in 10 fractions, followed by a sequential tumor-bed boost of 7.4 Gy in 2 fractions according to clinical indications. The primary endpoint was the incidence of grade ≥2 acute radiation dermatitis; secondary endpoints included patient-reported outcomes, cosmetic assessment, oncologic outcomes and exploratory immune profiling. Clinical Trial registration: ChiCTR2300075391. RESULTS: All patients completed radiotherapy without interruption. Tumor-bed boost was delivered to 58 patients (90.6%). Grade 2 acute dermatitis was observed in 17.2% of patients, with no grade ≥3 events, and all reactions resolved to grade 0-1 within three months. Among the 11 cases with grade 2 dermatitis, the most frequently affected site was the nipple-areola complex (6 cases, 54.5%). Patient-reported cosmetic and breast symptom scores transiently worsened at two weeks after radiotherapy but recovered thereafter. No significant decline occurred in functional or global quality-of-life domains. Exploratory analyses suggested that prior chemotherapy and lower baseline CD4 CONCLUSION: This 10-fraction whole-breast radiotherapy regimen was acceptable. These findings support this regimen as a practical alternative for adjuvant breast radiotherapy.